Peter’s scientific background lies in the field of condensed matter physics, biophysics, and bioinformatics. He was a top-2 cited Russian physicist under 35 and has conducted research at the Kurchatov Institute (one of the leading science government agencies in Russia), AMOLF (a national research center in the Netherlands), and the University of Innsbruck.
Peter studied theoretical physics at the Moscow Institute of Physics and Technology (MIPT) and obtained his Ph.D. from the University of Amsterdam. He currently has over 70 publications in peer-reviewed journals and multiple patents. As an MIPT researcher and head of the Biological Systems Simulation Lab, he works on modeling complex biological systems using methods borrowed from statistical physics, kinetics, and physical dynamics.
As a biotech entrepreneur, he has led projects in research and pre-clinical development of anti-inflammatory, anti-infectious, and anti-aging compounds, technology licensing, and drug discovery collaborations with academia and major pharma companies, including members of the World Top 20.
Peter is the founder and CEO of Gero LLC. Gero is an AI-driven drug discovery company using big human medical data to identify innovative therapeutics. Gero’s flagship project is a pipeline of longevity therapeutics; recent results include experimental therapies rejuvenating and reducing biological age and frailty in mice. Gero works with leading academic partners—including Brian Kennedy, Aubrey de Grey, Robert J. Shmookler Reis, Vadim Gladyshev, Yuri Aulchenko, Andrei Gudkov, and others—to translate aging biology into life-changing interventions against biological aging acceleration in cancer, metabolic disorders, and immunosenescence.
